Drug General Information
Drug ID	D04EON
Former ID	DIB010565
Drug Name	BAL-101553
Indication	Cancer [ICD9: 140-229; ICD10:C00-C96]		Phase 1/2	[525257]
Company	Basilea Pharmaceutica International Ltd
Structure		Download 2D MOL 3D MOL
Canonical SMILES	Cl.Cl.c1(c(non1)NCCC#N)c1n(c2ccccc2n1)CC(=O)c1ccc(cc1)N<br />C(=O)[C@@H](N)CCCCN
Target and Pathway
Target(s)	Tubulin beta	Target Info	Inhibitor	[533035]
KEGG Pathway	Phagosome
	Gap junction
	Pathogenic Escherichia coli infection
NetPath Pathway	FSH Signaling Pathway
	TCR Signaling Pathway
	EGFR1 Signaling Pathway
PANTHER Pathway	Cytoskeletal regulation by Rho GTPase
	Huntington disease
Reactome	Regulation of PLK1 Activity at G2/M Transition
	Loss of Nlp from mitotic centrosomes
	Recruitment of mitotic centrosome proteins and complexes
	Loss of proteins required for interphase microtubule organization?from the centrosome
	Anchoring of the basal body to the plasma membrane
WikiPathways	Parkin-Ubiquitin Proteasomal System pathway
	Pathogenic Escherichia coli infection
	Mitotic G2-G2/M phases
References
Ref 525257	ClinicalTrials.gov (NCT02490800) Phase 1/2a Study of Oral BAL101553 in Adult Patients With Solid Tumors.
Ref 533035	Initial testing (stage 1) of BAL101553, a novel tubulin binding agent, by the pediatric preclinical testing program. Pediatr Blood Cancer. 2015 Jun;62(6):1106-9.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.